Application of salizotan in preparation of medicine for treating inflammatory bowel disease

Salizotan overcomes the shortcomings of existing treatments by inhibiting multiple IBD-related pathological processes, achieving effective treatment and relief of inflammatory bowel disease, and has promising application prospects.

CN118903126APending Publication Date: 2024-11-08TIANJIN JIKUN MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411237431.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing treatments for inflammatory bowel disease (IBD) suffer from low drug response rates, drug resistance, and adverse reactions from long-term use. There is a need to find new IBD targets to improve treatment efficacy and provide more treatment options.

Method used

Sarizotan was used as a small molecule drug to prepare a treatment for inflammatory bowel disease. It achieves the treatment of IBD by inhibiting weight loss, shortening of the colon, reducing goblet cells in the intestinal mucosa, deforming or disappearing crypts, inflammatory cell aggregation, and reducing mucin loss.

Benefits of technology

Salizotan effectively inhibited DSS-induced IBD in mice, including weight loss, colon shortening, reduction of goblet cells in the intestinal mucosa, crypt deformation, and inflammatory cell aggregation. It also reduced mucin loss in the intestinal barrier, slowed IBD progression, and had no adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903126A_ABST
    Figure CN118903126A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to application of Sarizotan in preparation of a medicine for treating inflammatory bowel diseases. The invention provides an application of salizotan in preparation of a medicine for treating inflammatory bowel diseases. The invention finds that Sarizotan has a good effect on IBD, has no adverse reaction, can inhibit weight loss, colon shortening, intestinal tissue mucous membrane layer goblet cell reduction, crypt deformation and even disappearance and inflammatory cell aggregation of DSS drinking water induced IBD mice, and slows down the development of the DSS drinking water induced IBD mice. Besides, compared with a biological agent which needs to be administrated in an intravenous or subcutaneous injection mode and is high in immunogenicity and prone to causing generation of an anti-drug antibody, the oral small-molecule medicine prepared from Sarizotan has the advantages of being small in molecular weight, capable of passing through cell membranes more easily and short in half-life period and has a good curative effect on IBD.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to the application of Sarizotan in the preparation of medicines for treating inflammatory bowel disease. Background Art

[0002] Inflammatory bowel disease (IBD) is a chronic inflammatory disease that mainly includes ulcerative colitis (UC) and Crohn's disease (CD). Although there are currently a variety of effective treatment options, including biologics and small molecule drugs such as infliximab, adalimumab, tofacitinib (JAK1, JAK3) mesalazine or upadacitinib, these therapies still have limitations, such as low drug response rates, drug resistance issues, and adverse reactions caused by long-term use. Therefore, continuing to search for new IBD targets in the gastrointestinal tract is of great significance for IBD drug development, which will not only help improve the treatment effect, but also provide patients with more treatment options. Summary of the invention

[0003] In order to solve the above problems, the present invention provides the use of sarizotan in the preparation of a drug for treating inflammatory bowel disease. The present invention finds that the small molecule drug Sarizotan has good efficacy on IBD, has no adverse reactions, and has good application prospects in treating, alleviating or improving IBD.

[0004] In order to achieve the above object, the present invention provides the following technical solutions:

[0005] The present invention provides the use of sarizotan in the preparation of a drug for treating inflammatory bowel disease, wherein the chemical structural formula of sarizotan is shown in Formula I;

[0006]

[0007] Preferably, the treatment of inflammatory bowel disease includes one or more of inhibiting weight loss, inhibiting colon shortening, inhibiting the reduction of goblet cells in the intestinal tissue mucosal layer, inhibiting the deformation or disappearance of intestinal tissue crypts, inhibiting the aggregation of inflammatory cells, reducing the loss of mucin in the intestinal barrier, and inhibiting the increase of calprotectin content.

[0008] Preferably, the mucin comprises acidic mucin.

[0009] The present invention provides a drug for treating inflammatory bowel disease, wherein each unit dose of the drug comprises 0.04 to 9 mg of sarizotan, and the chemical structural formula of the sarizotan is shown in Formula I;

[0010]

[0011] Preferably, the drug further comprises a pharmaceutically acceptable excipient.

[0012] Preferably, the pharmaceutically acceptable excipient includes one or more of pharmaceutically acceptable salts, esters and hydrates.

[0013] Preferably, the pharmaceutically acceptable salt includes one or more of hydrochloride, sulfate and nitrate.

[0014] Preferably, the pharmaceutically acceptable ester includes one or more of alkyl esters, cycloalkyl esters, aryl esters, heteroaryl esters and heteroalicyclic esters.

[0015] Preferably, the pharmaceutically acceptable hydrate includes one or more of hydrochloride hydrate, succinate hydrate and EDTA dimethyl salt dihydrate.

[0016] Preferably, the dosage form of the drug includes one or more of tablets, capsules, pills, suppositories, aerosols, oral liquid preparations, granules, powders, injections, syrups, wine preparations, tinctures, lotions and films.

[0017] Beneficial effects:

[0018] The present invention provides the use of sarizotan in the preparation of drugs for treating inflammatory bowel disease. The present invention found that Sarizotan has good efficacy on IBD, has no adverse reactions, can inhibit weight loss, colon shortening, goblet cell reduction in the intestinal mucosal layer, crypt deformation or even disappearance, and inflammatory cell aggregation in IBD mice induced by DSS drinking water, and slow down the progression of IBD in mice induced by DSS drinking water. In addition, compared with biological preparations that need to be administered by intravenous or subcutaneous injection and whose greater immunogenicity easily leads to the production of anti-drug antibodies, the oral small molecule drug prepared by Sarizotan has the characteristics of small molecular weight, easier to pass through the cell membrane and short half-life, and has good therapeutic effect on IBD. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.

[0020] Figure 1 The body weight change curves of mice in each group;

[0021] Figure 2 This is the disease activity index scoring curve of each group of mice;

[0022] Figure 3 The colorectal pictures and colorectal length statistics of mice in each group; * indicates p<0.05, *** indicates p<0.001, which means there is a statistically significant difference;

[0023] Figure 4The figure shows the calprotectin content of mice in each group; **** indicates p<0.0001, which means there is a statistically significant difference;

[0024] Figure 5 HE staining results of colon pathological sections of mice in each group;

[0025] Figure 6 The results of Alcian blue staining of colon pathological sections of mice in each group;

[0026] in, Figure 5 and Figure 6 The scale bars in the upper and lower images of different groups are 1000 μm and 200 μm, respectively. DETAILED DESCRIPTION

[0027] The present invention provides the use of sarizotan in the preparation of a drug for treating inflammatory bowel disease, wherein the chemical structural formula of sarizotan is shown in Formula I;

[0028]

[0029] In the present invention, the treatment of inflammatory bowel disease preferably includes one or more of inhibiting weight loss, inhibiting colon shortening, inhibiting the reduction of goblet cells in the intestinal tissue mucosal layer, inhibiting the deformation or disappearance of intestinal tissue crypts, inhibiting the aggregation of inflammatory cells, reducing the loss of mucin in the intestinal barrier and inhibiting the increase of calprotectin content; the mucin preferably includes acidic mucin.

[0030] The present invention finds that Sarizotan has a good effect on IBD without adverse reactions, can inhibit weight loss, colon shortening, goblet cell reduction in the intestinal mucosal layer, crypt deformation or even disappearance, and inflammatory cell aggregation in IBD mice induced by DSS drinking water, and slows down the progression of IBD in mice induced by DSS drinking water.

[0031] The present invention also provides a drug for treating inflammatory bowel disease, wherein each unit dose of the drug comprises 0.04 to 9 mg of sarizotan, and the chemical structural formula of the sarizotan is shown in Formula I;

[0032]

[0033] In the present invention, the drug preferably comprises 1.25-5 mg of sarizotan per unit dose, and more preferably comprises 2.5-5 mg of sarizotan. The unit dose of the present invention is suitable for oral administration, and the drug is suitable for mice per kg body weight.

[0034] In the present invention, the drug preferably further comprises a pharmaceutically acceptable excipient; the pharmaceutically acceptable excipient preferably comprises one or more of a pharmaceutically acceptable salt, an ester and a hydrate; the pharmaceutically acceptable salt preferably comprises one or more of a hydrochloride, a sulfate and a nitrate; the pharmaceutically acceptable ester preferably comprises an alkyl ester. 、 One or more of cycloalkyl esters, aryl esters, heteroaryl esters and heteroalicyclic esters; the pharmaceutically acceptable hydrate preferably includes one or more of hydrochloride hydrate, succinate hydrate and EDTA dimethyl salt dihydrate; the dosage form of the drug preferably includes one or more of tablets, capsules, pills, suppositories, aerosols, oral liquid preparations, granules, powders, injections, syrups, wines, tinctures, lotions and films.

[0035] In order to further illustrate the present invention, the application of sarizotan provided by the present invention in the preparation of drugs for treating inflammatory bowel disease is described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.

[0036] Example 1

[0037] Effects of sarizotan on DSS drinking water-induced IBD mouse model

[0038] Preparation of IBD animal model: Wild-type C57BL / 6J mice (8-10 weeks old) were selected and allowed to eat and drink freely during the adaptation period. At the beginning of the experiment, 50g / L dextran sulfate sodium (DSS) solution was first given to the mice for drinking. After 24 hours, the 50g / L DSS solution was replaced with 30g / L DSS solution (except for the normal control group), and the mice were allowed to drink freely. (The daily drinking water volume of each mouse was calculated as 6mL, and sufficient DSS solution was supplemented the next day. The DSS solution was given for a total of 8 days.)

[0039] Grouping: The control group was gavaged with the same volume of normal saline; the model group was given DSS modeling in the above manner, 50 g / L DSS solution on the first day, and 30 g / L DSS solution in drinking water on the second day until the end of the experiment; the positive drug group was given mesalazine once a day by gavage starting from the second day, and the positive control group was given 100 mg / kg body weight (i.e. 100 mpk) of mesalazine for 6 consecutive days; the dosages of Sarizotan low-, medium- and high-dose groups were 1.25 mg / kg body weight (i.e. 1.25 mpk), 2.5 mg / kg body weight (i.e. 2.5 mpk) and 5 mg / kg body weight (i.e. 5 mpk), respectively, and the mice were given mesalazine once a day by gavage starting from the second day for 6 consecutive days. The weight of mice was recorded once a day. 24 hours after the initial administration of DSS, mice were found to have soft stools, diarrhea or bloody stools. The disease and activity index score (DAI, see Table 1) was scored and recorded every day. After 7 days of administration, the feces (3 to 5 grains) of each mouse were collected on the 8th day and frozen at -80°C. All mice were killed by cervical dislocation, the abdominal cavity of mice was exposed, the colorectum was dissected and the length was measured; the colorectum was cut longitudinally along the mesentery, the feces were washed with PBS, fixed with 4% paraformaldehyde solution, and then dehydrated, paraffin embedded, sectioned, and stained with hematoxylin-eosin (HE) to observe the tissue lesions under a microscope and score them; some colorectal tissues were frozen in a -80°C refrigerator, and tissue inflammatory factors and barrier proteins were subsequently detected.

[0040] Record of mouse weight changes: Record the weight of mice every week for 8 days. Statistic the weight of mice. Observe the weight changes of mice for 8 days.

[0041] Table 1 Body weight and disease activity index score

[0042]

[0043]

[0044] Note: The basic body weight is the body weight on the day of model establishment.

[0045] Colorectal sampling and length statistics: On the 8th day, the mice were killed by cervical dislocation, the abdominal cavity of the mice was exposed, and the colorectum (cecum to anus) was dissected and photographed, and the length was measured and statistically mapped.

[0046] Calprotectin content determination: Wash the fecal sample 3 times with PBS, take 20 mg and add 180 μL PBS to dissolve (final fecal mass: PBS volume = 1 g: 9 mL), crush by ultrasound (or mash), and centrifuge at 5000×g for 10 minutes. Take the supernatant for detection of mouse fecal calprotectin ELISA kit.

[0047] HE staining and Alcian blue staining of colorectal tissue pathological sections: The mouse colorectal tissue was first fixed with paraformaldehyde for 18 hours, the intestinal roll was taken out and fixed (the center of the roll near the anus, the outside of the intestinal mucosa side) for another 48 hours, and after routine dehydration, paraffin embedding, sectioning, HE staining / Alcian blue staining, and neutral gum sealing, HE staining image data was collected using an upright microscope.

[0048] The results are as follows Figure 1 to Figure 6 shown.

[0049] Depend on Figure 1 and Figure 2 It can be seen that after 8 days of DSS drinking, the body weight of the model group decreased significantly and the disease activity index increased compared with the control group, while high-dose sarizoltan can significantly alleviate the weight loss and increased disease activity index of mice induced by DSS drinking.

[0050] Depend on Figure 3 It can be seen that sarizoltan significantly reversed the shortening of colorectal length in IBD mice induced by DSS drinking water.

[0051] Depend on Figure 4 It can be seen that the administration of sarizoltan can significantly reduce the increase in fecal calprotectin content induced by DSS drinking water, indicating that sarizoltan can alleviate the severity of experimental colitis and the difference is statistically significant.

[0052] Depend on Figure 5 It can be seen that HE staining observation showed that the goblet cells and crypts in the control group had normal morphology, no ulcers, and no inflammatory cell aggregation. The goblet cells in the model group disappeared, the crypts were deformed to form cryptitis, and a large number of inflammatory cells gathered. The number of goblet cells and crypt morphology were significantly restored after sarizoltan.

[0053] Acidic mucin is an important component of the intestinal barrier. Figure 6 The results of Alzheimer's blue staining showed that both the low-dose and high-dose groups of sarizoltan could reduce the loss of mucin in the intestinal barrier of IBD mice.

[0054] In summary, Sarizoltan has a good effect on IBD, has no adverse reactions, can inhibit the weight loss, colon shortening, goblet cell reduction, crypt deformation and even disappearance, and inflammatory cell aggregation of IBD mice induced by DSS drinking water, reduce the loss of mucin in the intestinal barrier of DSS-induced IBD mice, and slow down the progression of IBD in mice induced by DSS drinking water. It has good application prospects in the treatment, relief or improvement of IBD.

[0055] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Use of sarizotan in the preparation of a drug for treating inflammatory bowel disease, wherein the chemical structure of sarizotan is shown in Formula I; 2. The use according to claim 1, characterized in that: The treatment of inflammatory bowel disease includes one or more of inhibiting weight loss, inhibiting colon shortening, inhibiting the reduction of goblet cells in the intestinal tissue mucosal layer, inhibiting the deformation or disappearance of intestinal tissue crypts, inhibiting the aggregation of inflammatory cells, reducing the loss of mucin in the intestinal barrier, and inhibiting the increase of calprotectin content.

3. The use according to claim 2, characterized in that: The mucin includes acidic mucin.

4. A drug for treating inflammatory bowel disease, characterized in that: Each unit dose of the drug includes 0.04 to 9 mg of sarizotan, and the chemical structural formula of sarizotan is shown in Formula I; 5. The drug according to claim 4, characterized in that The drug also includes pharmaceutically acceptable excipients.

6. The drug according to claim 5, characterized in that The pharmaceutically acceptable excipients include one or more of pharmaceutically acceptable salts, esters and hydrates.

7. The drug according to claim 6, characterized in that The pharmaceutically acceptable salt includes one or more of hydrochloride, sulfate and nitrate.

8. The drug according to claim 6, characterized in that The pharmaceutically acceptable ester includes one or more of alkyl esters, cycloalkyl esters, aryl esters, heteroaryl esters and heteroalicyclic esters.

9. The drug according to claim 6, characterized in that The pharmaceutically acceptable hydrate includes one or more of hydrochloride hydrate, succinate hydrate and EDTA dimethyl salt dihydrate.

10. The drug according to any one of claims 4 to 9, characterized in that The dosage form of the drug includes one or more of tablets, capsules, pills, suppositories, aerosols, oral liquid preparations, granules, powders, injections, syrups, wine preparations, tinctures, lotions and films.